2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
April 22nd 2021
Ravi Vij, MD, MBA, discusses the integration of selinexor into the relapsed/refractory multiple myeloma armamentarium.
April 13th 2021
Ravi Vij, MD, MBA, discusses the potential of cereblon E3 ligase modulators in relapsed/refractory multiple myeloma.
October 20th 2018
Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the optimal induction therapy in the treatment of patients with multiple myeloma.
April 9th 2015
Ravi Vij, MD, associate professor, medicine, Division of Oncology, Section of Bone Marrow Transplant, Siteman Cancer Center, discusses the institution's tumor banking initiative for next-generation sequencing in multiple myeloma.